P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments

P4ML's Expertise in Genomic Patient Identification, Ties to Middle East Health Initiatives and Irish Biopharmaceutical Roots to be Utilized in Support of OTXL's Mission & Programs CAMBRIDGE, Mass., Feb. 25, 2026 /PRNewswire/ -- P4ML, a Future100 company headquartered in the UAE, has been...